Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Section 3: Phasic Insulin Release and Metabolic Control

Lipotoxicity in Human Pancreatic Islets and the Protective Effect of Metformin

  1. Roberto Lupi1,
  2. Silvia Del Guerra1,
  3. Vanna Fierabracci2,
  4. Lorella Marselli1,
  5. Michela Novelli2,
  6. Giovanni Patanè3,
  7. Ugo Boggi4,
  8. Franco Mosca4,
  9. Salvatore Piro3,
  10. Stefano Del Prato1 and
  11. Piero Marchetti1
  1. 1Department of Endocrinology and Metabolism, Metabolic Unit, University of Pisa, Pisa, Italy
  2. 2Department of General Pathology, University of Pisa, Pisa, Italy
  3. 3Deparment of Endocrinology, University of Catania, Catania, Italy
  4. 4Department of Oncology, University of Pisa, Pisa, Italy
    Diabetes 2002 Feb; 51(suppl 1): S134-S137. https://doi.org/10.2337/diabetes.51.2007.S134
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Abstract

    Human pancreatic islets from eight donors were incubated for 48 h in the presence of 2.0 mmol/l free fatty acid (FFA) (oleate to palmitate, 2 to 1). Insulin secretion was then assessed in response to glucose (16.7 mmol/l), arginine (20 mmol/l), and glyburide (200 μmol/l) during static incubation or by perifusion. Glucose oxidation and utilization and intra-islet triglyceride content were measured. The effect of metformin (2.4 μg/ml) was studied because it protects rat islets from lipotoxicity. Glucose-stimulated but not arginine- or glyburide-stimulated insulin release was significantly lower from FFA-exposed islets. Impairment of insulin secretion after exposure to FFAs was mainly accounted for by defective early-phase release. In control islets, increasing glucose concentration was associated with an increase in glucose utilization and oxidation. FFA incubation reduced both glucose utilization and oxidation at maximal glucose concentration. Islet triglyceride content increased significantly after FFA exposure. Addition of metformin to high-FFA media prevented impairment in glucose-mediated insulin release, decline of first-phase insulin secretion, and reduction of glucose utilization and oxidation without significantly affecting islet triglyceride accumulation. These results show that lipotoxicity in human islets is characterized by selective loss of glucose responsiveness and impaired glucose metabolism, with a clear defect in early-phase insulin release. Metformin prevents these deleterious effects, supporting a direct protective action on human β-cells.

    Free fatty acids (FFAs) act as potent signaling molecules in several cellular processes, including insulin secretion (1,2). Experimental evidence indicates that prolonged exposure to high FFA concentrations has detrimental effects on β-cells (lipotoxicity), including reduced glucose-simulated insulin release, suppressed proinsulin biosynthesis, and β-cell loss by apoptosis (2,3). Thus, prolonged exposure to high FFAs may generate alterations of β-cells, as in type 2 diabetes (4). How this applies to humans, however, is still controversial. The 24-h infusion of triglyceride inhibited insulin release in control subjects (5), and reduction of plasma FFAs in first-degree relatives of type 2 diabetic subjects improved acute insulin secretion (6). On the other hand, Boden et al. (7) found that prolonged fat infusion stimulated insulin release. Zhou and Grill (8) reported decreased glucose-induced insulin release in human islets incubated for 48 h with 0.125 mmol/l palmitate or oleate. Finally, elevated FFA concentrations were associated with an increased proinsulin/insulin ratio (9), a marker for β-cell dysfunction.

    In the present report, we restudied the effect of elevated FFAs on isolated human pancreatic islets. Moreover, because metformin was recently shown to protect rat islets from lipotoxicity (10), its effect on human islets was determined.

    RESEARCH DESIGN AND METHODS

    Pancreatic islets were isolated from eight donors and cultured in M199 medium as reported (11). Islet aliquots were maintained for 48 h at 37°C in M199 with or without 2.0 mmol/l FFA (oleate to palmitate, 2 to 1; Sigma, St. Louis, MO), with 2% human albumin. Then insulin secretion was studied in batch incubations (6–8 independent pancreases) or by perifusion (four pancreases), as described (11,12). Insulin was measured by immunoradiometric assay (Pantec Forniture Biomediche, Turin, Italy). Glucose utilization and oxidation were assessed (islets from five pancreases) by measuring the formation of 3H2O from [5-3H]glucose and 14CO2 from [U-14C]glucose, respectively, as described (13). Intra-islet triglyceride concentration was measured by a commercial kit (GPO-Trinder; Sigma) after extraction (13). The effect of a therapeutic concentration (2.4 μg/ml) of metformin (Laboratori Guidotti, Pisa, Italy) was assessed by adding the drug (11) to the 48-h incubation media.

    Results are given as means ± SD. Statistical analysis was performed by the two-tailed Student’s t test or analysis of variance (ANOVA) (plus the Bonferroni correction).

    RESULTS

    Incubation of human islets in high-FFA medium was associated with a significant impairment of glucose-stimulated insulin release (56.7 ± 12.6 vs. 28.3 ± 6.9 pmol · islet−1 · 45 min−1; P < 0.05), whereas the response to arginine or glyburide was unchanged (Table 1). Metformin did not affect insulin secretion in response to glucose alone. When the drug was added with high FFA, the inhibition of glucose-induced insulin release was prevented (Table 1). The results of perifusion experiments are shown in Fig. 1. These confirmed that pre-exposure to FFAs decreased insulin secretion, mainly accounted for by a reduction of early-phase insulin release (Fig. 1A and B). As in batch incubations, metformin alone did not affect insulin release (Fig. 1C), whereas it abolished the suppressive effect of high FFAs (Fig. 1D).

    In control islets, glucose utilization and oxidation increased significantly in response to 16.7 mmol/l glucose (Table 2). The 48-h incubation with 2.0 mmol/l FFA blunted both glucose utilization (71.5 ± 22.6 vs. 135.8 ± 47.7 pmol · islet−1 · 120 min−1) and oxidation (24.7 ± 7.0 vs. 44.9 ± 13.3 pmol · islet−1 · 120 min−1; P < 0.05 for both). Metformin had no effect in control incubations, but its addition to high-FFA medium was associated with normalization of glucose fluxes.

    In control islets, triglyceride content was 15.0 ± 2.1 ng/islet and increased to 25.4 ± 2.5 ng/islet upon culture in a high-FFA medium (P < 0.05). In the islets cultured in the presence of both FFA and metformin, triglyceride content (21.3 ± 3.0 ng/islet) remained higher than that in control islets (P < 0.05).

    DISCUSSION

    We show that in human islets, high FFA levels cause selective loss of glucose responsiveness, which is particularly manifest during the first minutes after glucose challenge (early-phase insulin release). In contrast, insulin secretion in response to arginine and glyburide was not affected. This suggests that in human islets, FFAs selectively impair the release of insulin mediated by glucose, possibly by interfering with its metabolism. In our study, we measured both glucose utilization and oxidation to confirm that high FFA levels hampered both processes. The hypothesis is therefore supported that FFA-induced inhibition of glucose-stimulated insulin release may be related, at least in part, to the glucose-FFA (Randle) cycle (14), i.e., increased availability of FFAs favors their oxidation, leading to impaired glucose metabolism by substrate competition. Indeed, reduced pyruvate-dehydrogenase activity has been observed in islets from rodents exposed to high FFA concentrations (15). In our experiments, incubation with high FFAs was associated with triglyceride accumulation in islets. The role of triglyceride content on islet function remains controversial (16,17) because several studies have shown marked impairment of insulin secretion by FFAs independent from islet triglyceride content. Also in this study, improvement of islet function by metformin was not associated with a significant reduction of triglyceride content, but with normalization of glucose utilization and oxidation. These effects of metformin on glucose metabolism in islets are similar to effects at the level of peripheral tissues (18). Our results with the therapeutic concentration of metformin are similar to findings in rat islets, in which metformin caused reduction of FFA oxidation (10). Moreover, metformin has been reported to prevent the development of diabetes in the Zucker diabetic fatty rat (19). Finally, treatment with drugs able to reduce plasma FFA levels or their oxidation, such as acipimox (6) or glitazones (19–21), can improve β-cell function, supporting the concept of interplay between FFAs and glucose metabolism.

    Overall, the results of the present study are consistent with the concept that raised concentrations of circulating FFAs may contribute to the development of abnormalities in human islet function. Drugs improving glucose utilization and oxidation at the islet level, such as metformin, can prevent the deleterious effects of FFAs. From a clinical point of view, these results lend support to intervention aiming at normalizing lipid metabolism and reducing plasma FFA levels.

    FIG. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Islet perifusion experiments (from four different pancreases) showing the dynamics of insulin secretion from control islets (A), islets pre-exposed for 48 h to 2.0 mmol/l FFA (B), metformin (2.4 μg/ml) alone (C), and FFA (2.0 mmol/l) plus metformin (2.4 μg/ml) (D). The flow rate was 1 ml/min.

    View this table:
    • View inline
    • View popup
    TABLE 1

    Insulin release from control, FFA-treated, and FFA-plus-metformin–treated islets

    View this table:
    • View inline
    • View popup
    TABLE 2

    Glucose utilization and oxidation in control, FFA-treated, and FFA-plus-metformin–treated islets

    Acknowledgments

    This work was supported in part by the Italian Ministero Università e Ricerca Scientifica e Tecnologica (COFIN 2000).

    Footnotes

    • Address correspondence and reprint requests to marchant{at}immr.med.unipi.it..

      Accepted for publication 30 June 2001.

      ANOVA, analysis of variance; FFA, free fatty acid.

      The symposium and the publication of this article have been made possible by an unrestricted educational grant from Servier, Paris.

    REFERENCES

    1. ↵
      Crespin SR, Greeough WB, Steinberg D: Stimulation of insulin secretion by long-chain free fatty acids: a direct pancreatic effect. J Clin Invest 52:1979–1984, 1973
    2. ↵
      McGarry JD, Dobbins RL: Fatty acid, lipotoxicity and insulin secretion. Diabetologia 42:128–138, 1999
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      Shimabukuro M, Higa M, Zhou YT, Wang MY, Newgard CB, Unger RH: Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats: role of serine palmitoyltransferase overexpression. J Biol Chem 273:32487–32490, 1998
      OpenUrlAbstract/FREE Full Text
    4. ↵
      Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 44:863–870, 1995
      OpenUrlAbstract/FREE Full Text
    5. ↵
      Paolisso G, Gambardella A, Amato L, Tortoriello R, D’Amore A, Varricchio M, D’Onofrio F: Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 38:1295–1299, 1995
      OpenUrlPubMedWeb of Science
    6. ↵
      Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno G, Gambardella A, Giugliano D, D’Onofrio F, Howard BV: Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type 2 diabetes. Diabetologia 41:1127–1132, 1998
      OpenUrlCrossRefPubMedWeb of Science
    7. ↵
      Boden G, Chen X, Rosner J, Barton M: Effects of a 48h fat infusion on insulin secretion and glucose utilization. Diabetes 44:1239–1242, 1995
      OpenUrlAbstract/FREE Full Text
    8. ↵
      Zhou YP, Grill V: Long-term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 80:1584–1590, 1995
      OpenUrlCrossRefPubMedWeb of Science
    9. ↵
      Bjorklund A, Grill V: Enhancing effects of long-term elevated glucose and palmitate on stored and secreted proinsulin-to-insulin ratios in human pancreatic islets. Diabetes 48:1409–1414, 1999
      OpenUrlAbstract
    10. ↵
      Patanè G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F: Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 49:735–740, 2000
      OpenUrlAbstract
    11. ↵
      Lupi R, Del Guerra S, Tellini C, Giannarelli R, Coppelli A, Lorenzetti M, Carmellini M, Mosca F, Navalesi R, Marchetti P: The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol 8:205–209, 1999
    12. ↵
      Marchetti P, Dotta F, Ling Z, Lupi R, Del Guerra S, Santangelo C, Realacci M, Marselli L, Di Mario U, Navalesi R: The function of pancreatic islets isolated from a type 1 diabetic patient. Diabetes Care 23:701–703, 2000
      OpenUrlFREE Full Text
    13. ↵
      Purrello F, Buscema N, Rabuazzo AM, Caltabiano V, Forte F, Vinci C, Vetri M, Vigneri R: Glucose modulated glucose transporter affinity, glucokinase activity and secretory response in rat pancreatic beta-cells. Diabetes 42:199–205, 1993
      OpenUrlAbstract/FREE Full Text
    14. ↵
      Zhou YP, Grill VE: Long-term exposure of rat pancreatic islets to fatty acid inhibits glucose-induced insulin secretion and biosyntesis through a glucose fatty acid cycle. J Clin Invest 93:870–876, 1994
    15. ↵
      Zhou YP, Berggren PO, Grill VE: A fatty acid-induced decrease in pyruvate dehydrogenase activity is an important determinant of beta-cell dysfunction in the obese diabetic db/db mouse. Diabetes 45:580–586, 1996
      OpenUrlAbstract/FREE Full Text
    16. ↵
      Segall L, Lameloise N, Assimacopoulos-Jeannet F, Roche E, Corkey P, Thumelin S, Corkey BE, Prentki M: Lipid rather than glucose metabolism is implicated in altered insulin secretion caused by oleate in INS-1 cells. Am J Physiol 277:E521–E258, 1999
      OpenUrlAbstract/FREE Full Text
    17. ↵
      De Souza CJ, Capotorto JV, Cornell-Kennon S, Wu YJ, Steil GM, Trivedi N, Weir GC: Beta-cell dysfunction in 48h glucose-infused rats is not a consequence of elevated plasma lipid or islet triglyceride levels. Metabolism 49:755–759, 2000
      OpenUrlCrossRefPubMedWeb of Science
    18. ↵
      Riccio A, Del Prato S, Vigili de Kreutzenberg S, Tiengo A: Glucose and lipid metabolism in non-insulin-dependent diabetes: effect of metformin. Diabete Metab 17:180–184, 1991
      OpenUrlPubMedWeb of Science
    19. ↵
      Sreenan S, Sturis J, Pugh W, Burant CF, Polonski KS: Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol 271:E742–E747, 1996
      OpenUrlAbstract/FREE Full Text
    20. Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraeegen EW: The insulin sensitizer BRL 49653 reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism 46:935–942, 1997
      OpenUrlCrossRefPubMedWeb of Science
    21. ↵
      Buckingam RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC, Clapham JC: Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47:1326–1334, 1998
      OpenUrlAbstract/FREE Full Text
    PreviousNext
    Back to top

    In this Issue

    February 2002, 51(suppl 1)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Lipotoxicity in Human Pancreatic Islets and the Protective Effect of Metformin
    (Your Name) has forwarded a page to you from Diabetes
    (Your Name) thought you would like to see this page from the Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Lipotoxicity in Human Pancreatic Islets and the Protective Effect of Metformin
    Roberto Lupi, Silvia Del Guerra, Vanna Fierabracci, Lorella Marselli, Michela Novelli, Giovanni Patanè, Ugo Boggi, Franco Mosca, Salvatore Piro, Stefano Del Prato, Piero Marchetti
    Diabetes Feb 2002, 51 (suppl 1) S134-S137; DOI: 10.2337/diabetes.51.2007.S134

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Lipotoxicity in Human Pancreatic Islets and the Protective Effect of Metformin
    Roberto Lupi, Silvia Del Guerra, Vanna Fierabracci, Lorella Marselli, Michela Novelli, Giovanni Patanè, Ugo Boggi, Franco Mosca, Salvatore Piro, Stefano Del Prato, Piero Marchetti
    Diabetes Feb 2002, 51 (suppl 1) S134-S137; DOI: 10.2337/diabetes.51.2007.S134
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • RESEARCH DESIGN AND METHODS
      • RESULTS
      • DISCUSSION
      • Acknowledgments
      • Footnotes
      • REFERENCES
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Altered β-Cell Distribution of pdx-1 and GLUT-2 After a Short-Term Challenge With a High-Fat Diet in C57BL/6J Mice
    • Physiological Consequences of Phasic Insulin Release in the Normal Animal
    Show more Section 3: Phasic Insulin Release and Metabolic Control

    Similar Articles

    Navigate

    • Current Issue
    • Online Ahead of Print
    • Scientific Sessions Abstracts
    • Collections
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.